MXI1 and prostate carcinoma: Inactivating point mutations in the retained MXD2 allele were initially identified in a rare subgroup of prostate cancers with cytogenetically detecTable 10q24-q25 deletions and subsequently in a larger and more common group of tumors harboring much smaller 10q25.2 deletions detectable only by fluorescence in situ hybridization [228,232].